UK-based Dr. Anthony Rudd and Dr. Robert Simister have been named as consultants for its DMT stroke clinical research program, of which the Phase 1 part in London is earmarked to begin in January 2022
Compound DMT
Visit article
Category Press Release
Companies Featured
Algernon PharmaceuticalsAlgernon is a clinical stage pharmaceutical company that is developing novel psychedelic molecules (based on DMT) for the treatment of stroke-related dysfunction.